Your browser doesn't support javascript.
loading
Mendelian randomization incorporating uncertainty about pleiotropy.
Thompson, John R; Minelli, Cosetta; Bowden, Jack; Del Greco, Fabiola M; Gill, Dipender; Jones, Elinor M; Shapland, Chin Yang; Sheehan, Nuala A.
  • Thompson JR; Department of Health Sciences, University of Leicester, Leicester, UK.
  • Minelli C; Population Health and Occupational Disease, NHLI, Imperial College London, London, UK.
  • Bowden J; MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
  • Del Greco FM; Center for Biomedicine, European Academy of Bolzano/Bozen (EURAC), Bolzano/Bozen, Italy.
  • Gill D; Department of Clinical Pharmacology and Therapeutics, Imperial College London, London, UK.
  • Jones EM; Department of Statistical Science, University College London, London, UK.
  • Shapland CY; Department of Health Sciences, University of Leicester, Leicester, UK.
  • Sheehan NA; Max Planck Institute for Psycholinguistics, Nijmegen, The Netherlands.
Stat Med ; 36(29): 4627-4645, 2017 Dec 20.
Article en En | MEDLINE | ID: mdl-28850703
ABSTRACT
Mendelian randomization (MR) requires strong assumptions about the genetic instruments, of which the most difficult to justify relate to pleiotropy. In a two-sample MR, different methods of analysis are available if we are able to assume, M1 no pleiotropy (fixed effects meta-analysis), M2 that there may be pleiotropy but that the average pleiotropic effect is zero (random effects meta-analysis), and M3 that the average pleiotropic effect is nonzero (MR-Egger). In the latter 2 cases, we also require that the size of the pleiotropy is independent of the size of the effect on the exposure. Selecting one of these models without good reason would run the risk of misrepresenting the evidence for causality. The most conservative strategy would be to use M3 in all analyses as this makes the weakest assumptions, but such an analysis gives much less precise estimates and so should be avoided whenever stronger assumptions are credible. We consider the situation of a two-sample design when we are unsure which of these 3 pleiotropy models is appropriate. The analysis is placed within a Bayesian framework and Bayesian model averaging is used. We demonstrate that even large samples of the scale used in genome-wide meta-analysis may be insufficient to distinguish the pleiotropy models based on the data alone. Our simulations show that Bayesian model averaging provides a reasonable trade-off between bias and precision. Bayesian model averaging is recommended whenever there is uncertainty about the nature of the pleiotropy.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Teorema de Bayes / Análisis de la Aleatorización Mendeliana / Pleiotropía Genética Tipo de estudio: Clinical_trials / Prognostic_studies / Systematic_reviews Límite: Adolescent / Adult / Female / Humans Idioma: En Año: 2017 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Teorema de Bayes / Análisis de la Aleatorización Mendeliana / Pleiotropía Genética Tipo de estudio: Clinical_trials / Prognostic_studies / Systematic_reviews Límite: Adolescent / Adult / Female / Humans Idioma: En Año: 2017 Tipo del documento: Article